|
|
|
WHO ARE YOUR LAM-EXPERIENCED PATIENTS?
|
When there's any question, consider Hepsera.
71% of lamivudine-resistant, pre-transplant patients (77/109) and 40% of lamivudine-resistant, post-transplant patients (64/159) treated with combination therapy (Hepsera added on to lamivudine) achieved undetectable HBV DNA at year 1 (<1,000 copies/mL).
0% resistance was demonstrated in lamivudine-resistant patients when Hepsera was added for combination therapy-for up to 3 years (HIV/HBV-coinfected patients and pre- and post-transplant patients).
Choose Hepsera-the #1 prescribed oral antiviral for the treatment of chronic hepatitis B.
Hepsera
adefovir dipivoxil
INDICATION AND USAGE Hepsera is indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function. For patients 12 to < 18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function.
|
|
| Rate this file (No vote yet) |
|
|
|
|
|
|
